- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Eye on Pharma: Xbrane to Shift Its Focus to Biosimilars
Xbrane’s lead biosimilar candidate is a ranibizumab product (referencing Lucentis), developed in collaboration with Stata, that is moving into a pivotal clinical trial. The study will enroll patients with wet age-related macular degeneration across 16 countries.
Xbrane Biopharma has announced that it will shift its focus from generic drugs to biosimilars. “The board of directors of Xbrane has decided to dedicate the absolute majority of the company's development resources to biosimilars going forward,” the drug maker announced in a statement on September 10.
As part of Xbrane’s shift to biosimilars, the company will only pursue further development of its generic long-acting risperidone, leuprolide, exenatide, and octreotide products if additional resources become available internally or via strategic partnerships. It will, however, continue to develop its long-acting triptorelin injectable, a treatment for advanced prostate cancer. The freed-up resources from generic development will allow the company to pursue its pipeline of biosimilars.
Click to read more about Xbrane.
Xbrane’s lead biosimilar candidate is a ranibizumab product (referencing Lucentis), developed in collaboration with Stata, that is moving into a pivotal clinical trial. The study will enroll patients with wet age-related macular degeneration across 16 countries. In July 2018, Xbrane and Stada announced their development agreement for the product, under which each organization will contribute equally to development expenses and share profits from commercialization of the proposed biosimilar. Additionally, Stada agreed to make an upfront payment to Xbrane of approximately $8.7 million to fund development.
Also under development by Xbrane are a certolizumab pegol product (referencing Cimzia) and a pegaspargase product (referencing Oncaspar) for the treatment of acute lymphocytic leukemia.
The company says that it is also beginning development of 2 products that have patents expiring between 2026 and 2028. Said chairman Anders Tullgren, “We see multiple attractive opportunities to address and we have decided to develop [2] biosimilars on [2] fast growing biologics with a current combined global sale well above [$5 billion] with patent expiration 2026-2028. Now is the right time to initiate development of biosimilars to these biologics and we see the opportunity to be ahead of the game and to be amongst the first to launch."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
